Tribe Capital Growth Corp I - Warrants (24/02/2026)
ATVCW
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.43M
Close$
Share Statistics
| Market cap | $3.43 Million |
|---|---|
| Enterprise Value | $1.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $326.77 |
| Beta | 0 |
| Outstanding Shares | 27,600,000 |
Return
| Return on Equity | -4165.92% |
|---|---|
| Return on Assets | -367.93% |
| Return on Invested Capital | -3423.86% |
Valuation & Multiples
| P/E Ratio | 0.03 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.78 |
| Debt to Equity | 4.8 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Liminatus Pharma, Inc. Warrants
4 employees
CEO: Chris Kim Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.